The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2
申请人:Jin Yun
公开号:US20130252963A1
公开(公告)日:2013-09-26
The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, or example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2
申请人:GLAXO GROUP LIMITED
公开号:US20150099756A1
公开(公告)日:2015-04-09
The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES
申请人:WAN Zehong
公开号:US20130178488A1
公开(公告)日:2013-07-11
The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.